Treatment journey and outcomes of patients with RRMM after quadruple-class exposure: a critical unmet need

Patients with relapsed or refractory multiple myeloma (RRMM) previously exposed to proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and anti-B-cell maturation antigen (BCMA) therapies, defined as quadruple-class exposed (QCEx), face poor prognoses and limited therapeutic options. This study retrospectively tracked treatment journeys of this population across lines of therapy (LOTs), documenting disease characteristics and clinical outcomes using deidentified electronic health record data from Flatiron Health database (January 2011-July 2025). In total, 21,112 patients with MM were identified; of these, 683 had QCEx RRMM, 241 initiated a subsequent (index) therapy, and 121 died before receiving an index therapy. At index, patients had a median 5 prior LOT (range, 1-14), 49.8% exhibiting quadruple-class refractory disease. The median age was 67 years (range, 37-85). The most common index regimens were G protein-coupled receptor class C group 5 D (GPRC5D) bispecific antibodies (17.8%), BCMA-targeted (11.6%), and chemotherapy-based (9.5%) regimens. Median event-free and overall survival were 5.0 months (95% CI, 4.0-5.8) and 15.6 months (95% CI, 12.2-22.0), respectively. Approximately 25% died before advancing to each additional LOT. These findings highlight the profound clinical unmet need among patients with QCEx RRMM. Early intervention with novel and effective therapies is crucial to improving outcomes.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2026-11-17
DOI
https://doi.org/10.1182/bloodadvances.2026021159
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment journey and outcomes of patients with RRMM after quadruple-class exposure: a critical unmet need

Jaclyn Davis, Doris K. Hansen, Krina K. Patel, Meghan I. Podolsky et al.
5 links
Blood Advances
Multiple Myeloma Research and Treatments
article

Treatment journey and outcomes of patients with RRMM after quadruple-class exposure: a critical unmet need

Jaclyn Davis, Doris K. Hansen, Krina K. Patel, Meghan I. Podolsky, Teofilia Acheampong, Fangyi Gu, Lin Wang
article en

Abstract

Patients with relapsed or refractory multiple myeloma (RRMM) previously exposed to proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and anti-B-cell maturation antigen (BCMA) therapies, defined as quadruple-class exposed (QCEx), face poor prognoses and limited therapeutic options. This study retrospectively tracked treatment journeys of this population across lines of therapy (LOTs), documenting disease characteristics and clinical outcomes using deidentified electronic health record data from Flatiron Health database (January 2011-July 2025). In total, 21,112 patients with MM were identified; of these, 683 had QCEx RRMM, 241 initiated a subsequent (index) therapy, and 121 died before receiving an index therapy. At index, patients had a median 5 prior LOT (range, 1-14), 49.8% exhibiting quadruple-class refractory disease. The median age was 67 years (range, 37-85). The most common index regimens were G protein-coupled receptor class C group 5 D (GPRC5D) bispecific antibodies (17.8%), BCMA-targeted (11.6%), and chemotherapy-based (9.5%) regimens. Median event-free and overall survival were 5.0 months (95% CI, 4.0-5.8) and 15.6 months (95% CI, 12.2-22.0), respectively. Approximately 25% died before advancing to each additional LOT. These findings highlight the profound clinical unmet need among patients with QCEx RRMM. Early intervention with novel and effective therapies is crucial to improving outcomes.

Blood Advances
The University of Texas MD Anderson Cancer Center (US), Moffitt Cancer Center (US), Bristol-Myers Squibb (United States) (US), Bristol-Myers Squibb (Sweden) (SE)
Good health and well-being
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon